ChBE Seminar Series -- Navin Varadarajan

*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************

Event Details
Contact

Amy Schneider
School of Chemical & Biomolecular Engineering
(404) 385-2299
info@chbe.gatech.edu

Summaries

Summary Sentence: ChBE hosts a weekly seminar throughout the year with invited lecturers who are prominent in their fields.

Full Summary: No summary paragraph submitted.

In addition to its annual lectures, ChBE hosts a weekly seminar throughout the year with invited lecturers who are prominent in their fields. Unless otherwise noted, all seminars are held on Wednesdays in the Molecular Science and Engineering Building ("M" Building) in G011 (Cherry Logan Emerson Lecture Theater) at 4 p.m. Refreshments are served at 3:30 p.m. in the Emerson-Lewis Reception Salon.

_____________

"Advancing Cancer Immunotherapy One Cell at a Time"

Navin Varadarajan, Assistant Professor, Department of Chemical and Biomolecular Engineering, University of Houston

Abstract:
Tumors are a complex mixture of tumor and host cells that have acquired the ability to proliferate and overcome programmed cell death, suppress the host immune response, and induce growth of blood vessels to sustain growth and promote metastasis.

The significance of the immune system in eliminating/suppressing the malignant cells and the ability of tumor cells and the surrounding host cells to co-opt mechanisms of immunosuppresion to enable survival is well documented. The objective of immunotherapy is to harness this specific immune response to not only enable an immediate and potent anti-tumor response but also provide lasting immunity, through the establishment of memory.

Indeed, immunotherapy infusing antibodies, vaccines, and cells has emerged as a very effective approach for the treatment of human malignancies, including ones refractory to conventional treatment regimens. Clinical trials have revealed the advantages of many immune-based therapies, including defined mechanisms of action, reduced deleterious off-target effects, and lower toxicities than conventional approaches. Immune-based therapies, such as allogeneic hematopoietic stem-cell transplantation (HSCT) and monoclonal antibodies are now considered the standard-of-care for many malignancies.

The engineering of either antibodies that aim to modulate the immune-system, or genetically modified immune cells, has enabled new challenges in the design and manufacture of these products, and in determining potency.

I will discuss single-cell technology platforms and molecular engineering approaches that we have developed to address these problems, and how these are being implemented to improve the efficacy of cancer immunotherapy.

 

Additional Information

In Campus Calendar
No
Groups

School of Chemical and Biomolecular Engineering

Invited Audience
Public
Categories
Seminar/Lecture/Colloquium
Keywords
No keywords were submitted.
Status
  • Created By: Amy Schneider
  • Workflow Status: Published
  • Created On: Aug 12, 2014 - 10:32am
  • Last Updated: Oct 7, 2016 - 10:08pm